Predictive factors for invasive fungal rhinosinusitis in diabetic patients: Systematic review and data re-analysis

Thwe Phyo Kan Nyunt,1,2 Joaquim Mullol,3 Kornkiat Snidvongs1,2

Abstract

This systematic review aims to identify prognostic factors for the overall survival of invasive fungal rhinosinusitis (IFRS) in patients with diabetes using original data from the existing published articles. Systematic searches of Medline, EMBASE, and Cochrane Library databases were performed to include articles from 1988 to 2019 using the terms: “fung*” AND “rhinosinusitis” AND “invasive” AND “diabetes OR ketoacidosis”. Data from 258 diabetic patients with IFRS (mean age 55.9 years, 55.6% male, 124 studies) were extracted for data analysis. The mortality rate was 31.8%. Seven variables: plasma glucose level, HbA1C, ketoacidosis, leukopenia, serum creatinine level, duration of diabetes, and the cavernous sinus extension were assessed. Univariate analysis was done for each variable and revealed that the cavernous sinus extension was a significant risk factor. Multivariable logistic regression analysis confirmed that the cavernous sinus extension independently predicted mortality in patients with diabetes (hazard ratio (HR) 2.6, 95% confidence interval (CI) 1.2 to 5.4, \( p = 0.01 \)). Kaplan Meier curve and Log-rank test were used for analyzing survival outcomes. The twelve-month overall survival rate of the patients with the cavernous sinus extension was 43.9% compared to 73.9% for the patients without the cavernous sinus extension (\( p = 0.01 \)). Appropriate treatment of this condition could enhance the survival outcomes.

Key words: rhinosinusitis, diabetic ketoacidosis, cavernous sinus, glycated haemoglobin A, creatinine, blood glucose, fungal

Introduction

Invasive fungal rhinosinusitis (IFRS) is a fatal disease with a 50-80% mortality rate and serious complications.1 The clinical presentations of IFRS which include headache, fever, facial swelling, facial pain, and symptoms of nearby structures invasion such as ophthalmoplegia and vision problems, are similar between the two most common fungi, aspergillosis and mucormycosis. Extensive tissue necrosis, angioinvasion, extensions into the orbit, intracranial complications and the cavernous sinus extension are common complications. The incidence of IFRS in diabetic patients is increasing along with the increasing prevalence of diabetes. The WHO announced that diabetes was the seventh leading cause of death in 2016.2 Early diagnosis, prompt treatment of the IFRS and restoration of the defective immune system are essential to improve the patient’s survival. The relationship between diabetes and prognosis of the IFRS is controversial. Hyperglycemia and acidosis in diabetic ketoacidosis (DKA) result in a rapid progression of IFRS and mortality.3 However, a greater survival rate of IFRS in patients with diabetes mellitus compared to other immunosuppressive conditions was reported.4 The diversity of treatment outcomes across studies is due to a great variety of the immune status among the diabetic patients in the studies. Multiple factors affecting the immune system include hyperglycemic state (high plasma glucose and HbA1C levels), ketoacidosis, polymorphonuclear cell function, duration of diabetes, diabetes with multiple organ impairments. To date, prognostic factors of IFRS in diabetic patients are not evident. This systematic review aims to identify the key prognostic factors which predict the overall survival of diabetic patients with IFRS using the pooled data from the existing published articles.
Material and Methods
This systematic review followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. Medline, EMBASE, and Cochrane database were searched using the terms: “fung*” AND “rhinosinusitis” AND “invasive” AND “diabetes OR ketoacidosis”. The last search was performed on 30 May 2019. Inclusion criteria were case reports or case series reporting IFRS patients with original data regarding diabetic condition, the disease extension, medical and surgical treatments, and survival outcomes. Data reported by the same authors or the same institutions was checked to exclude any duplication. Articles were excluded when duplication was uncertain. Case series were excluded when the data of individual patients were not separately reported. Articles in a language other than English were excluded. Diagnostic criteria for diabetes mellitus were fasting plasma glucose values ≥ 7.0 mmol/L (126 mg/dl), a 2-hour post-load plasma glucose level ≥ 11.1 mmol/L (200 mg/dl), HbA1c ≥ 6.5% (48 mmol/mol); or a random plasma glucose ≥ 11.1 mmol/L (200 mg/dl) with the presence of signs and symptoms.7,8 Diagnostic criteria for IFRS were radiological imaging and histopathological evidence of hyphal forms within the sinus mucosa, submucosa, blood vessels, or bone.7

Study selection was performed independently by two reviewers (TPKN and KS). The reviewers independently screened the titles and abstracts based on the predetermined eligibility criteria. The full texts of the selected articles were reviewed. Data were extracted from the included studies using a predetermined data collection spreadsheet. Six prognostic factors related to diabetes (plasma glucose level, HbA1C, ketoacidosis, leukopenia, blood creatinine level, and duration of diabetes,) and one prognostic factor related to IFRS extension (the cavernous sinus extension) were evaluated. The outcome was overall survival. Time to event was measured from the initial diagnosis of invasive fungal sinusitis to death. Univariate analysis was done for each variable. Variables with potential risks were incorporated to multivariate analysis. Backward stepwise Cox proportional hazard model was run to assess potential hazard ratio. Kaplan Meier curve and Log-rank test were used for analyzing survival outcomes. STATA 15 was used for the data analysis. A p-value less than 0.05 was considered statistically significant.

Results
Study selection
A total of 1,014 articles were identified by systematic searches. There were 119 duplicates. The titles and the abstracts of 895 studies were screened, 462 full texts were reviewed, and 338 studies were excluded after the full text review. The reasons for exclusion are listed in Figure 1. Finally, 124 studies were included for data synthesis.6,15 A flow chart of the study retrieval and selection is presented in Figure 1.

Patients
There were 258 diabetic patients with IFRS. The mean age was 55.9 years and 55.6% were male. There was a wide geographical distribution. Most patients were from India (17%), followed by USA (16%), Korea (14%), Iran (9%) Turkey (8%), Germany (3%), Taiwan (3%) and Japan (3%). Type II diabetes was 87.2% and type I was 12.8%. Thirteen patients (5.0%) were newly diagnosed with type II diabetes at the time of admission. Most patients (71.4%) had poor glycemic control. Fifty-one patients (19.8%) had diabetic ketoacidosis.

Mucormycosis accounted for 62.9% and aspergillosis accounted for 24.2% of the IFRS patients. Three patients (1.0%) had both mucormycosis and aspergillosis. Other types of fungi such as Candida species and Absida corymbifera accounted for 3.6%. The type of fungal hyphae was not specified in 8.6% of the patients. The mean duration of symptoms was 22.7 ± 37.6 days. Two-hundred and forty-one patients (93.4%) were diagnosed with acute IFRS and 17 patients (6.7%) were chronic IFRS. The mean duration of symptoms in acute IFRS was 12.7 ± 15 days and chronic IFRS was 103 ± 67 days. Symptoms and signs were reported in 229 patients (118 records): 152 patients (66.4%) had complaints of eye symptoms and 77 patients (33.6%) had headaches. Black eschar was the most common sign. Fourteen patients (6.1%) did not have black mucosa or necrosis. Radiological imaging was reported in 245 patients (120 records), 129 patients (52.7%) had orbital invasion and 50 patients (20.4%) had the cavernous sinus invasion. The data from 120 records showed that 221 out of the 229 patients received antifungal treatment, 89% were treated with Amphotericin B derivatives (68% received Amphotericin B derivatives as a sole agent). Among patients who received Amphotericin B derivatives, 69% of the patients improved and survived. Eight patients did not receive antifungal treatment due to renal failure, multiorgan failure and severe medical

Figure 1. Prisma flow diagram on the selected manuscripts for analysis
Invasive fungal sinusitis outcomes

conditions. Of the total 258 patients, 221 patients (85.6%) underwent a surgical treatment, 165 patients (63.9%) underwent endoscopic approach.

**Prognostic factors and overall survival analysis**

Follow-up time was reported in 207 patients (120 records). The data were used for overall survival analysis. The mortality rate was 31.8%. The mean follow-up time was 11.4 ± 18.0 months (range 0.6-120 months). Plasma glucose levels were reported in 70 patients (52 records). The mean plasma glucose level was 391.3 ± 216.4 mg/dl and 56 patients (80%) had plasma glucose above 200 mg/dl. HbA1c levels were reported in 32 patients (21 records). The mean HbA1c was 9.7 ± 2.8 and 10 patients (32%) had HbA1c greater than 11. The duration of having diabetes before admission was reported in 56 patients (44 records). The mean duration of having diabetes was 5.6 ± 6.2 years. Nineteen patients (33%) had less than one-year duration, 21 (38%) between 1-10 years and 16 (29%) above ten years. White blood cell counts were reported in 55 patients (42 records). The mean total white blood cell count was 13,576.0 ± 8,846.5 × 10³ cell per liter. Six patients (10%) had a total white blood cell count less than 4,000 cell per liter, 18 (33%) had 4,000-11,000 and 31 (57%) had greater than 11,000. Serum creatinine was reported in 35 patients (24 records). The mean serum creatinine level was 1.5 ± 0.8 mg/dl. Twenty-eight patients (79%) had serum creatinine level greater than 1 mg/dl. Fifty-one patients (24.6%) had ketoacidosis. Radiological imaging was reported in 245 patients (120 records). Fifty patients (20%) had the cavernous sinus extension.

Table 1. Prognostic factors on overall survival of invasive fungal rhinosinusitis in diabetic patients

| Risk factors                      | Univariate analysis |          |          |          | Multivariate analysis |          |          |
|----------------------------------|---------------------|----------|----------|----------|-----------------------|----------|----------|
|                                  | Hazard ratio        | 95% CI   | P-value  | Hazard ratio| 95% CI         | P-value  |          |
| Age                              | 1.00                | 0.98     | 1.01     | 0.86      | 1.00                | 0.98     | 1.02     | 0.76     |
| Diabetes ketoacidosis            | 0.68                | 0.39     | 1.17     | 0.16      | 1.57                | 0.72     | 3.43     | 0.26     |
| Cavernous sinus involvement      | 2.09                | 1.2      | 3.6      | 0.01      | 2.56                | 1.21     | 5.40     | 0.01     |
| Plasma Glucose                   | 2.05                | 0.61     | 6.96     | 0.25      |                      |          |          |          |
| HbA1C                            | 0.38                | 0.05     | 3.14     | 0.37      |                      |          |          |          |
| Total WBC count                  | 1.22                | 0.55     | 2.72     | 0.62      |                      |          |          |          |
| Creatinine                       | 1.68                | 0.20     | 14.01    | 0.63      |                      |          |          |          |
| Duration of DM                   | 1.07                | 0.56     | 2.04     | 0.63      |                      |          |          |          |

Kaplan-Meier survival estimates

Figure 2. Overall survival of diabetic patients with invasive fungal rhinosinusitis with and without the cavernous sinus extension

| Number at risk | Months from admission |
|----------------|-----------------------|
|                | 0  | 2  | 4  | 6  | 8  | 10 | 12 | 14 | 16 | 18 | 20 | 22 | 24 |
| Cav sinus = 0  | 154| 107| 93 | 83 | 61 | 56 | 52 | 39 | 34 | 30 | 27 | 27 | 27 |
| Cav sinus = 1  | 41 | 25 | 23 | 17 | 14 | 13 | 12 | 8  | 7  | 6  | 4  | 3  | 3  |
The univariable logistic regression analysis revealed that the cavernous sinus extension was a significant risk factor (hazard ratio (HR) 2.1, 95% confidence interval (CI) 1.2 to 3.6, \( p = 0.01 \)). As a potential risk factor, diabetic ketoacidosis was assessed using multivariate analysis together with the cavernous sinus extension. The multivariable logistic regression analysis showed that the cavernous sinus extension independently predicted poor prognosis (HR 2.6, 95% CI 1.2 to 5.4, \( p = 0.01 \)). The data are displayed in Table 1. In the patients with the cavernous sinus extension, the overall survival at two months, six months and 12 months was 69.7%, 57.1%, and 43.9%, respectively. These overall survivals were significantly lower than those of the patients without the cavernous sinus extension (80.9%, 75.1% and 73.9%, respectively, \( p = 0.01 \)). The data are displayed in Figure 2.

Discussion

In this review, the mortality rate of IFRS in diabetic patients was 31.8% which was lower than the mortality rate of IFRS in the general population (50-80 %). In line with our review, a systematic review by Turner, et al. showed that IFRS in patients with diabetes had twice the overall survival than patients with other underlying diseases. Mucormycosis accounted for 62.9% in this systematic review. Invasive fungal rhinosinusitis in patients with diabetic ketoacidosis is mainly mucor infection rather than aspergillus infection because diabetic patients have excess iron available in the tissues and Mucors can use the excess iron to grow and spread. In addition, diabetes patients have reduced defensive cells such as neutrophils and macrophages and reduced chemotaxis and phagocytosis of the host. When the raw data of individual case reports were pooled, our findings showed that the cavernous sinus extension was an independent factor which predicted the overall survival of diabetic patients with IFRS. Angioinvasion and vascular thrombosis caused by IFRS lead to the cavernous sinus extension. A basic research by Frater et al. assessed histologic features of disease and the fungal morphology in 20 patients with zygomycosis. Hyphal invasion of arterial and venous walls was seen in angioinvasion (100%), and prominent infarcts (94%). Additionally, prominent perineural invasion (90%) was present in most patients. Clinical presentations of cavernous sinus extension may include bilateral exophthalmos, complete ophthalmoplegia, lid drop, and signs of meningeal irritation associated with spiking fevers. Similar to the cavernous sinus thrombosis in acute bacterial rhinosinusitis, our review showed that the cavernous sinus extension by IFRS was fatal.

The cavernous sinus is a dangerous area for endoscopic sinus and skull base surgeries due to its neurovascular structures. Therefore, the cavernous sinus extension is a hard-to-treat condition. Although other variables also have potential risks, they are correctable resulting in more favorable outcomes. Understanding immunopathology of the underlying immunocompromised diseases and restoration of the host immune dysfunction are essential for treating IFRS together with adequate surgery and appropriate antifungal treatments. Diabetes Mellitus affects both the humoral and cellular immune responses of the innate and adaptive immune systems. The expression of class I major histocompatibility complex is impaired. The structure of complement and the balance between complement activation and restriction are altered. In poorly controlled diabetes, hyperglycemia diminishes vascular dilation and activates protein kinase C which inhibits polymorphonuclear cells production, neutrophil migration, chemotaxis and phagocytic activity. Furthermore, diabetic ketoacidosis causes an overexpression of the glucose-induced glucose-regulated protein (GRP) 78 which induces endothelial cell damage and fungal invasion. In addition, when acidosis is present, iron is released from its binding proteins which regulates endothelial cell damage. Iron and the overexpression of glucose-induced GRP78 enhance endothelial cell susceptibility to R. oryzae-induced fungal invasion leading to endothelial damage. Germination and rapid filamentous growth of mucormycosis within the endothelial damage, the exposed basement membrane and extracellular matrix proteins cause angiointeruption, vessel thrombosis, and necrosis.

IFRS is a fatal disease, therefore, neurological examination together with radiological imaging investigation should be performed to evaluate the cavernous sinus and intracranial extension. Magnetic resonance venography may be requested in specific cases for the assessment of the cavernous sinus extension. Diabetic ketoacidosis and hyperglycemic state should be assessed and treated.

The limitations of this systematic review included a retrospective nature of the included studies, and publication bias. Disadvantages of case reports and case series included missing data, confounders, and risks of bias. There were multiple factors which contributed to publication bias. Investigators commonly avoided submitting the results which were not supported by the known findings. Poor therapeutic outcomes and high mortality rate were not reported probably due to the investigators’ assumption that they had made mistakes. On the other hand, publishers are not interested in the null results. In addition, most journals prefer high quality studies. Preregistered studies prior to data collection and analysis are preferred by several journals. Thus, a limited number of studies could be included.

Conclusion

Therapeutic outcomes of invasive fungal rhinosinusitis in diabetic patients are diverse. The disease extension into the cavernous sinus predicts a high mortality rate. In practice, restoration of the immune function and a total disease eradication could improve the treatment outcomes. Patients can have favorable overall survival when diabetic conditions are well controlled.

Acknowledgement

The authors would like to acknowledge Professor Maung Maung Khaing for his technical advice.
Conflict of Interest

- Joaquim Mullol is or has been member of the advisory boards for GSK, Meda-Mylan Pharma, MSD, Novartis, SANOFI-Regeneron, AstraZeneca, and URIACH. He received Honoraria for speaking at symposia from GSK, SANOFI-Regeneron, Menarini, Meda-Mylan Pharma, MSD, URIACH, UCB, and Novartis. He received grants for research projects and clinical trials from MEDA-Mylan, SANOFI-Regeneron, GSK, Roche-Novartis, and URIACH.

- Kornkiat Snidvongs received Honoraria for speaking at symposia from Merck Sharp & Dohme, and Menarini

- Thwe Phyoe Kyun Nyunt has no conflict of interest.

Authors contribution

- Thwe Phyoe Kyun Nyunt: literature search, study selection, data collection, drafting the article, and final approval

- Joaquim Mullol: expert opinion, revising the article, and final approval

- Kornkiat Snidvongs: conception, literature search, data collection, drafting the article, and final approval

References

1. Gillespie MB, O’Malley, Bert W Jr, Francis HW. An Approach to Fulminant Invasive Fungal Rhinosinusitis in the Immunocompromised Host. Arch Otolaryngol Head Neck Surg. 1998;124(5):520-6.

2. World Health Organization [Internet]. Geneva: WHO; c2020 [cited 2020 Jun 8]. Diabetes; [about 5 screens]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes

3. Jung SH, Kim SW, Park CS, Song CE, Cho IH, Lee JH, et al. Rhinocerebral Mucormycosis: consideration of prognostic factors and treatment modality. Auris Nasus Larynx. 2009;36(3):274-9.

4. Saedi B, Sadeghi M, Seilani P. Endoscopic management of rhinocerebral mucormycosis with topical and intravenous amphotericin B. J Laryngol Otol. 2011;125(8):807-10.

5. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1(Suppl 1):S62-9.

6. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030, PLoS Med. 2006;3(11):e442

7. deShazo RD, O’Brien M, Chapin K, Soto-Aguilar M, Gardner L, Swain R. Rhinocerebral mucormycosis: a report of two atypical cases. Ear Nose Throat J. 2011;90(2):118-22.

8. Afruz SN, Korlepara R, Béclis N, Pullukçu H, et al. Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: A case report. Turk Neuroloji Dergisi. 2017;23(2):225-8.

9. Al-Ajam MR, Bizri AR, Mokhbat J, Lutwick L. Mucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology. Contemp Clin Dent. 2017;8(4):662-6.

10. Al-Jamr MR, Burzi AR, Mokhbat J, Lutwick L. Mucormycosis in the Eastern Mediterranean: A seasonal disease. Epidemiol Infect. 2006;134(3):341-6.

11. Alaye AD, Vannier A, Sperati F, Detwiler PW. Long-term survival of a patient with invasive cranial base rhinocerebral mucormycosis treated with combined endovascular, surgical, and medical therapies: case report. Neurosurgery. 1999;45(6):E146-1.

12. Alsuhaibani A, Al-Thubaiti G, Al Badr F. Optic nerve thickening and infarction as the first evidence of orbital involvement with mucormycosis. Middle East Afr J Ophthalmol. 2012;19(3):340-2.

13. Anders UM, Taylor EI, Martel JR, Martel JB. Acute orbital apex syndrome and rhino-orbito-cerebral mucormycosis. Int Med Case Rep J. 2015;8:93-6.

14. Arndt S, Aschendorff A, Echternach M, Daemmrich TD, Maier W. Rhino-orbital-cerebral mucormycosis and aspergillosis: Differential diagnosis and treatment. Eur Arch Otorhinolaryngol. 2009;266(1):71-6.

15. Arora V, Nagarkar NM, Dass A, Malhotra A. Invasive Rhino-Orbital Aspergillosis. Indian J Otolaryngol. 2011;63(4):325-9.

16. Baban TA, Raad RA, Dandachi D, Kanj SS, Kanafani ZA. Three cases of mucormycosis from the middle east: Different risk factors leading to different outcomes. Journal of Invasive Fungal Infections. 2011;5(4):E112-22.

17. Babishhae M, Bojdi A, Allahyari A, Majidi MR, Takavol S, Najafzadeh MJ, et al. Acute invasive fungal rhinosinusitis: our experience with 18 cases. Eur Arch Oto-Rhino-L. 2016;273(12):4281-7.

18. Baskhi SS. An unusual cause for facial nerve palsy: mucormycosis. Int J Diabetes Dev C. 2016;36(4):385-8.

19. Balasubramaniam P, Madakara PB, Ninam An, Swaminathan A. Response of central nervous system aspergillosis to voriconazole. Neurol India. 2007;55(3):301-3.

20. Busaba NY, Colden DG, Faquin WC, Salman SD. Chronic invasive fungal sinusitis: A Report of two atypical cases. Ear Nose Throat J. 2002;81(7):462-6.

21. Cabot RC, Scully RE, Mark EJ, McNeely BU, Diamond RD, Proppe KH. Case 38-1982: A 66-Year-Old Diabetic Woman with Sinusitis and Cranial Nerve Abnormalities. N Engl J Med. 1982;307(13):806-14.

22. Çagatay AA, Öncü SS, Çalangu SS, Yildirmak TT, Özsüt HH, Eraksoy HH. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: A case report. BMC Infect Dis. 2001;1(1):22.

23. Castillo L, Hofman V, Béclis N, Piche M, Roger PM, Santini J, et al. Long-term survival in acute rhinocerebral mucormycosis with giant cell arteritis and foreign body granulomas. Pathol Res Pract. 2000;197(3):199-203.

24. Chan JCW, Yu DKH, Lee DLY, Abdullah VJ, Li KKW. Combined lateral orbitotomy and endoscopic transsphenoidal orbital decompression in a case of orbital aspergillosis with impending intracranial invasion. Case Rep Ophthalmol. 2012;3(3):418-23.

25. Chander J, Kaur J, Gulati N, Arora V, Nagarkar N, Sood S, et al. Sudden vision loss caused by rhino-orbital zygomycosis in diabetic patients: case series. Mycoses. 2011;54(4):228-32.

26. Chavez JA, Brat DJ, Hunter SB, Vega JV, Guerner J. Practical diagnostic approach to the presence of hyphae in neuropathology specimens with three illustrative cases. Am J Clin Pathol. 2018;149(2):98-104.

27. Chi T-H, Chen H-S, Yuan C-H, Su F-M. Acute fulminant invasive fungal sinusitis with cavernous sinus syndrome. JCPSP. 2014;24 Suppl 3(9066447):S240-2.

28. Chitsaz S, Bagheri J, Mandegar MH, Rayatzadeh H, Razavi J, Azadi L. Excessive Sino-Orbital Zygomyces After Heart Transplantation: A Case Report. Transplant Proc. 2009;41(7):2927-9.

29. Cho HH, Jung MS, Hong SD, Chung SK, Kim HY, Dhung HJ. Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2011;25(1):48-53.

30. Choi HS, Choi JY, Yoon JS, Kim SJ, Lee SY. Clinical characteristics and prognosis of orbital invasive aspergillosis. Ophthal Plast Recon. 2008;24(6):454-9.

31. Chu JLL, Cullen JF. Fungal pan-sinusitis with severe visual loss in uncontrolled diabetes. Ann Acad Med Singap. 2008;37(11):964-7.

32. Chun HM, Skelton SC, Armstrong AW. Paranosal mucormycosis in a patient with AIDS presenting as a palatal mass. Infect Dis Clin Pract. 2006;14(4):235-8.

33. Çolak AY, Gökçay F, Çelebiysy N, Gökçay A, Güler A, Pullukçu H, et al. Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: A case report and literature review. Rev Soc Bras Med Tro. 2011;44(2):257-9.

34. Dhurawani R, Asrani S, Pathak S, Sharma A. Facial translocation type 1 diabetes: A case report and review of the literature. Ital J Pediatr. 2013;39(1).
38. Dinowitz M, Leen JS, Hameed M, Wolansky L, Frohman L. Sudden painless visual loss. Surv Ophthalmol. 2001;46(2):143-8.
39. Erami M, Shams-Ghaftarokhi M, Jahanshiri Z, Sharif A, Razzaghi-Abyaneh M. Rhinocerebral mucormycosis due to Rhizopus oryzae in a diabetic patient: A case report. J Mycol Med. 2013;23(2):123-9.
40. Escamilla Carpentero Y, Espasa Soley M, Bella Cueto MR, Prenafeta Moreno M. Sphenoid sinusitis with intracranial extension produced by an emergent fungus. Acta Otorrinolaringol Esp. 2011;62(2):158-60.
41. Fu KA, Nguyen PL, Sanossian N. Basilar artery territory stroke secondary to invasive fungal sphenoid sinusitis: A case report and review of the literature. Case Rep Neurol. 2015;7(1):51-8.
42. Giglio M, Caggiano G, De Blasi R, Cucchiara V, Ladisa P, et al. A fatal rhino-cerebral zygomycosis in a young woman with latent diabetes mellitus and cerebral blood vessel agenesis. Med Mycol J. 2010;48(2):394-7.
43. Gupta R, Gupta B, Bal A, Gupta AK. Sinonasal mucormycosis with fungal ball: A rare case report. Clin Rin Roh. 2014;7(2):e64-6.
44. Gutiérrez-Delgado EM, Treviño-González JL, Montemayor-Alatorre A, Cerecías-Falcón LA, Ruiz-Holguitén E, Andrade-Vázquez CJ, et al. Chronic rhino-orbito-cerebral mucormycosis: A case report and review of the literature. Am Med. 2016;6:87-91.
45. Hadzri MH, Azarisman SM, Fauzi AR, Kahairi A. Invasive rhinocerebral mucormycosis with orbital extension in poorly-controlled diabetes mellitus. Singapore Med J. 2009;50(5):e107-e9.
46. Hendrickson KG, Oshaker J, Deckert O. Rhinocerebral mucormycosis: A case of a rare, but deadly disease. J Emerg Med. 1999;17(4):641-5.
47. Hoenigl M, Aspeck E, Valentin T, Heiling B, Seeber K, Krause R, et al. Rhinocerebral mucormycosis in the era of lipid-based amphotericin B. J Eur Acad Dermatol Venereol. 2006;20 Suppl 1(nof, 8805008):37-41.
48. Huang Y, Gui L. Cavernous sinus-orbital apex aspergillus infection in a diabetic patient: A case report. Oral Radiol Endod. 2007;104(5):e28-34.
49. Hosseini SMS, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol. 2005;262(2):932-8.
50. Huang JS, Kok SH, Lee JJ, Hsu WY, Chiang CP, Kuo YS. Extensive maxillary sequestration resulting from mucormycosis. Brit J Oral Max Surg. 2005;43(6):532-4.
51. Horowitz A, Spendel D, Kraut R, Orentlicher G. Cavernous sinus thrombosis as a result of a fungal infection: A case report. J Oral Maxillofac Surg. 2013;71(11):1899.e1-e5.
52. Hosseini SMS, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol. 2005;262(2):932-8.
53. Jacob NB, Chaney S. Rhino Orbito Cerebral Mucormycosis: A Fatal Acute Invasive Fungal Infection in Uncontrolled Diabetes. Jnp-J Nurse Pract. 2016;12(10):667-74.
54. Javadzadeh Bolouri A, Delavarian Z, Dalirsani Z, Tonkaboni A. Chronic invasive Aspergillus sinusitis and otitis with meningeal extension. Pak J Med Sci. 2011;27(4):911-4.
55. Jhuo SJ, Wang WS, Kuo JY. Successful treatment of Aspergillus sinusitis with oral voriconazole: A case report. J Intern Med Taiwan. 2007;18(4):177-80.
56. Juhász A, Bényei E, Máczi G, et al. Case report and review of the literature. Acta Otorhinolaryngol Hung. 2005;56(2):157-64.
57. Karakurum B, Karatas M, Cagici AC, Uncu H, Yildirim T, Hurcan C, et al. Rhinocerebral mucormycosis caused by Rhizopus oryzae. J Infect. 2007;55(3):e33-e6.
58. Kulendra K, Habibi M, Butler C, Clarke P. Howard D. Use of posaconazole in the treatment of infective rhinocerebral mucormycosis. J Laryngol Otol. 2010;124(12):1314-7.
59. Lee DH, Yoon TM, Lee JK, Joo YE, Park KH, Lim SC. Invasive fungal sinusitis of the sphenoid sinus. Clin Exp Otorhinolaryngol. 2014;7(3):181-7.
60. Li CH, Lay CJ, Ho YH, Wang LS, Wang CL, Tsai CC. Successful treatment of two cases of invasive aspergillus sinusitis with voriconazole. Tzu Chi Med J. 2010;22(2):106-10.
61. Li DM, Shang PP, Zhu L, De Hoog GS. Rhino-orbito-cerebral mucormycosis and cavernous thrombosis. Eur J Infiamm. 2014;12(1):1-10.
62. Mahomed S, Banasht S, Misana K. The successful use of amphotericin B followed by oral posaconazole in a rare case of invasive fungal sinusitis caused by co-infection with mucormycosis and aspergillus. IDCases. 2015;2(4):116-7.
63. Mane RS, Patil BC, Mohite AA. Rhinocerebral infection presenting as oozantinal fistula. Clin Rhinol 2012;5(3):133-7.
64. Mathuram AJ, Mohanraj P, Mathews RS. Rhino-orbito-cerebral infection causing Sincephalatraenum racemosumus. J Assoc Physicians India 2013;61(5):339-41.
65. Meas T, Mouluy S, Kania R, Hervé D, Herman P, Kévorkian JP, et al. Zygomycosis: An uncommon case for peripheral facial palsy in diabetes. Diabetes Metab. 2007;33(3):227-9.
66. Mimouni O, Curto CL, Danvin JB, Thomassin JM, Dessi P. Sinonasal mucormycosis. Case report. Eur Arch Otorhinolaryngol Head Neck Dis. 2010;127(1):27-9.
67. Mohamed MS, Abdel-Moteleb HY, Mobarak FA. Management of rhino-orbit mucormycosis. Saudi Med J. 2015;36(7):865-8.
68. Mohammadi R, Meidani M, Mostafavizadeh K, Iraj B, Hamedani P, Sayedain SMA, et al. Case series of rhinocerebral mucormycosis occurring in diabetic patients. Casiap J Intern Med. 2015;6(4):243-6.
69. Morel RM, MMY, Fang PWH, Choy BY, Chan TM. Invasive fungal rhinosinusitis presenting as Bell's palsy in a kidney and liver transplant recipient. J Formos Med Assoc. 2017;116(11):910-1.
70. Mondy KE, Haughey B, Custer PL, Wippold FJ, Ritchie DJ, Mundy LM. Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: Case report and literature review. Pharmacotherapy. 2002;22(4):519-26.
71. Murgand M, Rammauer B, Poirée S, Bougnoux ME, Tran H, Kania R, et al. Chronic invasive Aspergillus sinusitis and otitis with meningial extension successfully treated with voriconazole. Antimicrob Agents Chemother. 2015;59(12):7857-61.
72. Moses AE, Rahav G, Barenholz Y, Eliadan J, Araz B, Gillis S, et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin Infect Dis. 1998;26(6):1430-3.
73. Mundra RK, Gupta Y. Mucormycosis of nose and paranasal sinuses with orbital complication in young diabetic. Indian J Otolaryngol Head Neck Surg. 2008;60(4):360-4.
74. Narayanvi S, Panarkandy G, Subramaniam G, Radhakrishnan C, Thulasidhearan NK, Manikath N, et al. The “black evil” affecting patients with diabetes: A case of rhino orbito cerebral mucormycosis causing Cushing syndrome. Infect Drug Resist. 2017;10:103-8.
75. Nenoff P, Kellermann S, Horn LC, Keiner S, Bootz F, Schneider S, et al. Case report. Mycotic arteritis due to Aspergillus fumigatus in a diabetic with retrobulbar aspergillosis and mycotic meningitis. Mycoses. 2001;44(9-10):407-14.
76. Norlinah MI, Ngow HA, Hamidon BB. Angloinvasive cerebral aspergillosis presenting as acute ischaemic stroke in a patient with diabetes mellitus. Singapore Med J. 2007;48(8):41-4.
77. Nothi G, Taranli L, Costantino F, Jansson A, Rosenecker J, Friederici D, et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses. 2006;49 Suppl 1(nof, 8805008):37-41.
Ochi JW, Harris JP, Feldman JL, Press GA. Rhinocerebral mucormycosis: Results of aggressive surgical debridement and amphotericin B. Laryngoscope. 1988;98(12):1339-42.

106. Oladje S, Amusa OA, Olaguesebi J, Adisa A. Rhinocerebral mucormycosis in a diabetic case report. J West Afr Coll Surg. 2013;3(1):93-102.

108. Pandey A, Bansal V, Asthana AK, Trivedi V, Madan M, Das A. Maxillary osteomyelitis by mucormycosis: Report of four cases. Int J Infect Dis. 2011;15(1):e66-e9.

109. Pinto ME, Manrique HA, Guevara X, Acosta M, Villena JE, Solís J. Hypersaline hyperosmolar state and rhino-orbital mucormycosis. Diabetes Res Clin Pract. 2011;92(1):e37-9.

110. Prasad K, Lalitha RM, Reddy EK, Ranganath K, Srinivas DR, Singh J. Role of early diagnosis and multimodal treatment in rhinocerebral mucormycosis: Experience of 4 cases. J Oral Maxillofac Surg. 2012; 70(2):354-62.

111. Rajmane VS, Rajmane ST, Patil VC, Patil AB, Mohite ST. Rhinocerebral mucormycosis due to Fusarium species leading to cavernous sinus thrombosis. J Mycol Med. 2013;23(1):53-6.

112. Rao S, Kumar K, Rokade V, Khanna V, Pal C. Orbital apex syndrome due to mucormycosis caused by Rhizopus microsporus. Indian J Otolaryngol. 2006;58(1):84-7.

113. Rassi S, Melkane AE, Rizk HG, Dahoui HA. Sino-orbital mucormycosis in immunocompromised pediatric patients. Pediatr Hematol Oncol. 2009; 31(12):907-10.

114. Raymundo IT, De Araújo BG, Costa CDC, Tavares JP, Lima CG, Rassi SJ, Melkane AE, Rizk HG, Dahoui HA. Mucormycosis mimicks sinustis in a diabetic adult. Ann N Y Acad Sci. 2006;1084:520-30.

115. Takahashi H, Hinozira Y, Hato N, Nishakakusa H, Hyodo J, Ugurumi T. et al. Clinical features and outcomes of four patients with invasive fungal sinustis. Auris Nasus Larynx. 2011;38(2):289-94.

116. Talmi YP, Goldschmied-Revouen A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhinor-oital and rhino-orbito-cerebral mucormycosis. Otolaryng Head Neck. 2002;127(1):22-31.

117. Talwalkar PC. Rhino-orbital-cerebral mucormycosis in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:407-9.

118. Tan KT, Ong PL, Poh WT, Cheah JS. Aspergillosis of sphenoid sinus presenting as a pituitary tumour. Singapore Med J. 1998;29(4):410-2.

119. Tarani L, Costantino F, Notheis G, Wintergerst U, Venditti M, Di Biasi GL, et al. Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatr Diabetes. 2009; 10(4):289-93.

120. Thajeb P, Thajeb T, Dai D. Fatal strokes in patients with rhino-orbital mucormycosis. Curr Med Chem. 2016;23(18):2283-91.

121. Timóteo CA, Corrêa APS, Coleté JZ, Aranega AM, Junior IRG. Survival without neurological impairment of a patient with rhino-orbital-cerebral mucormycosis. J Craniofac Surg. 2016;27(4):e376-8.

122. Tugsel Z, Sezer B, Akalin T. Facial swelling and palatal ulceration in a diabetic patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98(6):630-6.

123. Ugurlu ŞK, Şelim S, Kopar A, Songu M. Rhinor-oital mucormycosis: Clinical findings and treatment outcomes of four cases. Turk oftalmol Derg. 2015;45(4):169-74.

124. Vaidyanathan V, Shetty K. Rhinocerebral mucormycosis: A series of 3 cases. Ann Trop Med 2012;125(6):591-3.

125. Valera FCP, Lago TD, Tamashiro CC, Silveira F, Anselmo -Lima WT. Prognosis of acute invasive fungal rhinosinusitis related to underlying disease. Int J Infect Dis. 2011;15(12):e641-6.e4.

126. Vos FJ. Retinsa AD, Admirsen GP, Fokkens WJ. Eye for an eye: Near-fatal outcome of fungal infection in a young, diabetic girl. BMJ Case Rep. 2018;2018:bcr2017223059.

127. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.

128. Wüppenhorst N, Lee MK, Rappold E, Kayser G, Beckervordersandforth J, De With K, et al. Rhinor-oital-cerebral zygomycosis caused by Rhizopus oryzae in a diabetic adult. Ann N Y Acad Sci. 2006;1084:520-30.

129. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.

130. Yoon JS, Park HK, Cho NH, Lee SY. Outcomes of three patients with rhino-orbitocerebral zygomycosis. Auris Nasus Larynx. 2011;38(5):322-8.

131. Yoon JS, Park HK, Cho NH, Lee SY. Outcomes of three patients with rhino-orbitocerebral zygomycosis. Auris Nasus Larynx. 2011;38(5):322-8.

132. Yoon JS, Park HK, Cho NH, Lee SY. Outcomes of three patients with rhino-orbitocerebral zygomycosis. Auris Nasus Larynx. 2011;38(5):322-8.

133. Turner JH, Soudry E, Nayak JV, Hwang PH. Survival outcomes in acute rhinocerebral zygomycosis. Am J Rhinol Allergy. 2015;29(1):48-52.

134. Vols FI, Retinsa AD, Admirsen GP, Fokkens WJ. Eye for an eye: Near-fatal outcome of fungal infection in a young diabetic girl. BMJ Case Rep. 2018;2018:bcr2017223059.

135. Vols FI, Retinsa AD, Admirsen GP, Fokkens WJ. Eye for an eye: Near-fatal outcome of fungal infection in a young diabetic girl. BMJ Case Rep. 2018;2018:bcr2017223059.

136. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.

137. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.

138. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.

139. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.

140. Wipfler P, Pilz G, Golaszewski S, Luthringshausen G, Berr F, Kemmerling J, De With K, et al. Rhino-orbital-cerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4325-7.
135. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001;125(3):375-8.

136. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79(8 Suppl):1527-34.

137. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914-24.

138. Schell WA. Unusual fungal pathogens in fungal rhinosinusitis. Otolaryngol Clin North Am. 2000;33(2):367-73.

139. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001;125(3):375-8.